EMvision Medical Devices Ltd. (AU:EMV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EMVision Medical Devices Ltd has announced impressive results from its groundbreaking neurodiagnostic technology designed to identify strokes and their types early. The EMView study, involving 307 participants, showed high sensitivity and specificity in detecting hemorrhagic and ischemic strokes, paving the way for a validation trial aimed at FDA clearance and commercialization. The trial is expected to cost $4 million and take 6-12 months, backed by the company’s cash reserves.
For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.